Exscientia Limited - ADR
News
Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Business Wire Exscientia plc (Nasdaq: EXAI) today announced that David Hallett, interim Chief Executive Officer and Chief Scientific Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual...\n more…
Morgan Stanley Sticks to Their Hold Rating for Exscientia Plc (EXAI)
TipRanks Financial Blog In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Exscientia Plc (EXAI - Research Report), with a price ta...\n more…
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
Fool.com Headlines Recursion Pharmaceuticals (NASDAQ: RXRX) and Exscientia (NASDAQ: EXAI) made waves on Aug. 8 when they announced plans to merge into one business, forming the world's largest biotech devoted to doing...\n more…
Exscientia reports Q2 results
SeekingAlpha.com: All News Read about Exscientia's Q2 business update for 2024 with a GAAP EPS of -$0.36 and a revenue increase of 47.4% YoY to $5.6M.\n more…
EXAI Stock Earnings: Exscientia Misses EPS, Misses Revenue for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nEXAI stock results show that Exscientia missed analyst estimates for earnings per share and missed on revenue for the second quarter of...\n more…
